menu
    • menu

    Company profile for Ridgeback Biotherapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman owned biotechnology company focused on orphan and infectious diseases. Ridgeback Biotherapeutics was founded by Wayne and Wendy Holman; two science driven individuals who invest in technologies that they believe will make the world a better place. The team at Ridgeback is dedicated to working toward finding life-saving and life cha...
    Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman owned biotechnology company focused on orphan and infectious diseases. Ridgeback Biotherapeutics was founded by Wayne and Wendy Holman; two science driven individuals who invest in technologies that they believe will make the world a better place. The team at Ridgeback is dedicated to working toward finding life-saving and life changing solutions for patients and diseases that need champions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ridgeback BiotherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    UNIT 402, MIAMI, FL 33133
    Telephone
    Telephone
    305-602-5172
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ridgebackbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ridgeback`s Biologic Ebanga Receives Suppl Approval in US
    Ridgeback`s Biologic Ebanga Receives Suppl Approval in US

    26 Dec 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761172

    FDA
    26 Dec 2024
    Share Share
    Merck & Ridgeback Start Ph 3 Study of LAGEVRIO™ for COVID-19
    Merck & Ridgeback Start Ph 3 Study of LAGEVRIO™ for COVID-19

    05 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241205097781/en

    BUSINESSWIRE
    05 Dec 2024
    Share Share
    Merck, Ridgeback withdraw COVID drug application in EU
    Merck, Ridgeback withdraw COVID drug application in EU

    27 Jun 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/merck-ridgeback-withdraw-covid-drug-application-eu-2023-06-27/

    REUTERS
    27 Jun 2023
    Share Share
    Merck and Ridgeback Provide Update on EU MAA for LAGEVRIO
    Merck and Ridgeback Provide Update on EU MAA for LAGEVRIO

    24 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230223006077/en

    BUSINESSWIRE
    24 Feb 2023
    Share Share
    NICE recommends against NHS use of 5 COVID treatments as not cost-effective
    NICE recommends against NHS use of 5 COVID treatments as not cost-effective

    17 Nov 2022

    // REUTERS

    https://www.reuters.com/world/uk/britains-nice-recommends-against-nhs-use-5-covid-treatments-not-cost-effective-2022-11-16/

    REUTERS
    17 Nov 2022
    Share Share
    Merck & Ridgeback Provide Update on Clinical & Non-Clinical Studies of LAGEVRIO
    Merck & Ridgeback Provide Update on Clinical & Non-Clinical Studies of LAGEVRIO

    06 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221006006068/en

    BUSINESSWIRE
    06 Oct 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search